EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE

Rena Buckstein iD, Jeannie Callum, Anca Prica, David Bowen, Richard A Wells, Brian Leber, Nancy Heddle iD, Lisa Chodirker, Matthew Cheung, Lee Mozessohn, Karen Yee, Jennifer Gallagher und 6 weitere

Transfusion · 2024

DOI: 10.1111/trf.17721 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Transfusion, 2024. Verfasst von Rena Buckstein und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Myelodysplastic Syndromes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Canadian Cancer Society Research Institute, MOSPI Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal hemoglobin (Hb) threshold for red blood cell transfusions in adult patients with myelodysplastic syndromes (MDS) has not been defined. Study Design and Methods We conducted a pilot randomized multi‐center study of two transfusion algorithms (liberal, to maintain Hb 110–120 g/L, transfuse 2 units if Hb < 105 g/L and 1 unit if Hb 105–110 g/L vs. restrictive, 85–105 g/L, transfuse 2 units when Hgb < 85 g/L). Primary objectives were 70% compliance in maintaining the q2 week hemoglobin within the targeted range and the achievement of a 15 g/L difference in pre‐transfusion Hb. Secondary outcomes included measures of quality of life (QOL), iron studies and safety.

Results

Twenty‐eight patients were randomized between February 2015–2020, 13 to the restrictive arm and 15 to the liberal arm in three tertiary care centers. The compliance was 66% and 45% and the mean pre‐transfusion Hb thresholds were 86 (standard deviation [SD] 8) and 98 g/L (SD 10) in the restrictive and liberal arms, (mean difference 11.8 g/L, p < .0001), respectively. Patients in the liberal arm experienced a mean of 3.4 (SD 2.6) more transfusion visits and received a mean of 5.3 (SD 5.5) more units of blood during the 12‐week study. Ferritin increased by 1043 (SD 1516) IU/L and 148 (SD 1319) IU/L in the liberal and restrictive arms, respectively. Selected QOL scores were superior pre‐transfusion and more patients achieved clinically important improvements in the liberal arm compared with the restrictive arm for selected symptoms and function domains.

Conclusion

The results establish that policies for transfusion support can be delivered in practice at multiple hospitals, but further research is required to understand the full clinical effects and safety of liberal transfusion policies in MDS outpatients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythrocyte TransfusionMyelodysplastic SyndromesAdultHumansQuality of LifeOutpatientsPilot ProjectsHemoglobins

Stichwörter der Autor:innen

RBC transfusionhematology-red cellstransfusion practices (oncology-hematology)

Substanzen

Hemoglobins

Autor:innen und Institutionen

  • Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre and Queen's University, Kingston, Ontario, Canada.
  • Department of Medicine, Princess Margaret Hospital, United Health Network, Toronto, Ontario, Canada.
  • Department of Medicine, University of York, York, UK.
  • Department of Medicine, Mcmaster University, Hamilton, Ontario, Canada.
  • Mcmaster Centre for Transfusion Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

ORCID-Profile: Rena Buckstein, Nancy Heddle, Yulia Lin

Förderung

  • Canadian Cancer Society Research Institute
  • MOSPI Fund

Zitieren

APA

Buckstein, R., Callum, J., Prica, A., Bowen, D., Wells, R. A., Leber, B., Heddle, N., Chodirker, L., Cheung, M., Mozessohn, L., Yee, K., Gallagher, J., Parmentier, A., Jamula, E., Zhang, L., Mamedov, A., Stanworth, S. J., & Lin, Y. (2024). Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE. Transfusion. https://doi.org/10.1111/trf.17721

Vancouver

Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, et al. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE. Transfusion. 2024. doi:10.1111/trf.17721

BibTeX
@article{Buckstein2024,
  author = {Buckstein, Rena and Callum, Jeannie and Prica, Anca and Bowen, David and Wells, Richard A and Leber, Brian and Heddle, Nancy and Chodirker, Lisa and Cheung, Matthew and Mozessohn, Lee and Yee, Karen and Gallagher, Jennifer and Parmentier, Anne and Jamula, Erin and Zhang, Liying and Mamedov, Alex and Stanworth, Simon J and Lin, Yulia},
  title = {Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17721}
}
Kostenlos starten →